Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in Panic Disorder
NCT02395510Phase 4Completed
- Sponsor
- Siyan Clinical Corporation
- Start
- May 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vortioxetine in panic disorder, sponsored by Siyan Clinical Corporation. Primary endpoints: Mean Change from Baseline in the Panic Disorder Severity Scale (PDSS) score at 10 weeks and Reduction in occurrence of panic attacks at 10 weeks. Started May 2015; status: completed.
02
Drugs
vortioxetine
03
Conditions
panic disorder
Beyond the preview
Go deeper on NCT02395510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395510.